YSYasuhiro Suzuki

Yasuhiro Suzuki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yasuhiro Suzuki has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroatsu Iida

    Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

    2 shared publications
  • Hirokazu Nagai

    Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

    2 shared publications
  • Hiromi Iwasaki

    Department of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

    2 shared publications
  • Kazutaka Sunami

    Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan

    2 shared publications
  • Maki Otsuka

    Department of Hematology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan

    2 shared publications
  • Michihiro Hidaka

    Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan

    2 shared publications

Latest Publications

  • Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma

    by Yasuhiro Suzuki, Takahiro Yano, Youko Suehiro, Hiromi Iwasaki, Michihiro Hidaka, Maki Otsuka, Kazutaka Sunami, Hirokazu Ikeda, Morio Sawamura, Takuo Ito, et al.

    Recently, progression of disease within 24 months (POD24) has been demonstrated as a strong prognostic indicator in various types of malignant lymphoma. Peripheral T-cell lymphoma (PTCL) has an aggressive course and poor clinical outcomes. In this multicenter retrospective study, 111 consecutively registered patients with newly diagnosed PTCL were analyzed. Of these patients, 72 (64.9%) experienced POD24 (POD24 group), and the other 39 patients (35.1%) were analyzed as the no POD24 group. In the POD24 group, overall survival (OS) was significantly inferior to all patients, and in the no POD24 group, subsequent OS was significantly superior to the POD24 group, although the clinical characteristics between the POD24 group and no POD24 group were not significantly different. Twenty-three patients (20.7%) showed primary refractory disease to first-line therapy, and the prognosis was poor. The International Prognostic Index score and POD24 were identified as independent predictors in multivariate analysis for OS in all patients, and only performance status was an independent prognostic factor for OS in the POD24 group in multivariate analysis. In conclusion, the clinical significance of assessing POD24 in PTCL and the poor prognosis in patients with early disease progression were demonstrated.


  • Open Access

    Effect of High-Flow Nasal Cannula on Sleep-disordered Breathing and Sleep Quality in Patients With Acute Stroke

    by Nobuto Nakanishi, Yasuhiro Suzuki, Manabu Ishihara, Yoshitoyo Ueno, Natsuki Tane, Yumiko Tsunano, Taiga Itagaki, Jun Oto

    Sleep-disordered breathing (SDB) is common after stroke. Although the standard treatment of SDB is continuous positive airway pressure (CPAP) ventilation, the patient’s intolerance and discomfort result in low adherence rates. Alternatively, high-flow nasal cannula (HFNC) may be useful as it reduces upper airway collapse with low level of positive pressure and well tolerability. The aim of this study was to investigate whether HFNC therapy reduces SDB and improves sleep quality with higher compliance rate. We included acute stroke patients with SDB for the assessment of apnea-hypopnea index (AHI) >5/h using WatchPAT 200 (Itamar Medical Ltd, Caesarea, Israel). Patients who met inclusion criteria received HFNC therapy (40 L/min) with monitoring by WatchPAT. AHI, oxygen desaturation index (ODI), sleep efficiency, and rapid eye movement (REM) sleep were compared in patients with and without HFNC therapy. We also evaluated the patient’s comfort of HFNC therapy (discomfort or not). Among 17 patients assessed for AHI, 12 received HFNC therapy. HFNC therapy was not adhered in two patients due to intolerance. Eight patients remained for final analysis. There were no differences in SDB and sleep quality with and without HFNC therapy as follows: HFNC therapy vs control; AHI 24.9 ± 20.1 vs 21.3 ± 15.0/h (p = 0.63), ODI 16.2 ± 16.5 vs 12.9 ± 12.3/h (p = 0.54), sleep efficiency 80.4 ± 12.9 vs 87.1 ± 6.2 (p = 0.28), percentage of REM sleep 19.4% ± 9.6% vs 27.6% ± 8.9% (p = 0.07). Two patients (17%) complained of discomfort among eight patients. HFNC therapy did not improve SDB and sleep quality. Nonadherence and discomfort were observed in HFNC therapy. We need a large trial to confirm this result.


  • Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults

    by Yasuhiro Suzuki, Takahiro Yano, Youko Suehiro, Hiromi Iwasaki, Michihiro Hidaka, Maki Otsuka, Kazutaka Sunami, Nobumasa Inoue, Morio Sawamura, Takuo Ito, et al.

    Clinical information regarding non-Hodgkin lymphoma (NHL) in adolescents and young adults (AYA) is lacking. We retrospectively analyzed 1426 consecutively registered patients with newly diagnosed NHL. Of 798 DLBCL patients, 42 (5.3%) were identified as AYA (16–39 years). The characteristics of AYA DLBCL patients showed no significant differences compared to older adult DLBCL patients (age ≥ 40 years). Progression-free survival (PFS) and overall survival (OS) in AYA were similar to those in patients aged 40–60 years. However, in older adult groups, PFS and OS were significantly different according to the age group (40–60, 61–79, and ≥ 80 years). In univariate analysis in AYA, performance status, clinical stage, International Prognostic Index (IPI), and age-adjusted IPI significantly affected both PFS and OS. In multivariate analysis, only clinical stage was identified as an independent predictor among AYA. In conclusion, disease characteristics and outcomes of DLBCL in AYA were nearly the same as those in older adults.